Reply: A proposition for the use of radioiodine in WDTC management

Journal of Nuclear Medicine

Volumn 50, Issue 2, 2009, Pages 329-330

  Hay, Ian D ^a   McDougall, I Ross ^b   Sisson, James C ^c  

^a MAYO CLINIC   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; THYROGLOBULIN ANTIBODY; THYROTROPIN;

CANCER RADIOTHERAPY; CANCER SURGERY; DIAGNOSTIC ACCURACY; DOSIMETRY; FOLLICULAR CARCINOMA; HORMONE RELEASE; LETTER; LYMPH NODE METASTASIS; MICROMETASTASIS; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; THYROIDECTOMY;

EID: 59249091389     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.057349     Document Type: Letter

References (13)

1. Hay ID, McDougall IR, Sisson JC. Perspective: the case against radioiodine remnant ablation in patients with well-differentiated thyroid carcinoma. J Nucl Med. 2008;49:1395-1397.
2. Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med. 2003;139:346-351.
3. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2005;90:5566-5575.
4. Bramley MD, Harrison BJ. Papillary microcarcinoma of the thyroid gland. Br J Surg. 1996;83:1674-1683.
5. Kovacs GL, Gonda G, Vadasz G, et al. Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. Thyroid. 2005;15:152-157.
6. Pazaitou-Panayiotou K, Capezzone M, Pacini F. Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid. 2007;17:1085-1092.
7. Roti E, Rossi R, Trasforini G, et al. Clinical and histologic characteristics of papillary thyroid microcarcinoma: results of a retrospective study of 243 patients. J Clin Endocrinol Metab. 2006;91:2171-2178.
8. Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR. Bergstralh EJ. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992;112:1139-1146.
9. Chow S-M, Law SKW, Chan JKC, Au S-K, Yau S, Lau W-H. Papillary microcarcinoma of the thyroid: prognostic significance of lymph node metastases and multifocality. Cancer. 2003;98:31-40.
10. McDougall IR, Carnargo CA. Treatment of micropapillary carcinoma of the thyroid: where do we draw the line? Thyroid. 2007;17:1093-1096.
11. D'Avanzo A, Treseler P, Ituarte PHG, et al. Follicular carcinoma: histology and prognosis. Cancer. 2004;100:1123-1129.
12. D'Avanzo A, Ituarte P, Treseler P, et al. Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Thyroid. 2004;14:453-458.
13. Haugen BR, Emerson C, Pacini F, et al. Expanding indications for recombinant human TSH in thyroid cancer. Thyroid. 2008;18:687-694.